加勒比、中美洲和南美洲的艾滋病毒感染者中的癌症。
Cancer in HIV-infected persons from the Caribbean, Central and South America.
机构信息
Huésped, Investigaciones Clínicas, Buenos Aires, Argentina.
出版信息
J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):467-73. doi: 10.1097/QAI.0b013e31820bb1c3.
BACKGROUND
HIV-infected individuals have heightened cancer risk. With the advent of highly active antiretroviral therapy (HAART), the frequency of some AIDS-defining cancers (ADC) has decreased although certain non-AIDS-defining cancers (NADC) are becoming more frequent. Cancers among HIV-infected individuals in Latin American and the Caribbean have not yet been carefully studied.
METHODS
Cancer cases among the Caribbean, Central and South American network for HIV Research (CCASAnet) cohort were identified reviewing clinical records and pre-existing databases.
RESULTS
There were 406 cancers reported: 331 ADC (224 Kaposi sarcomas and 98 non Hodgkin lymphomas). Most frequent NADC (n = 75) were Hodgkin lymphoma and skin cancers. Seventy-three percent of NADC and 45% of ADC were diagnosed >1 year after HIV diagnosis. Fifty-six percent of ADC occurred before HAART start. Median time from HAART start until cancer diagnosis was 2.5 years for NADC and 0.5 years for ADC (P = <0.001). Within 3372 HAART starters, 158 were diagnosed with 165 cancers (82.4% ADC); 85 cases were previous to or concomitant with HAART initiation. Incidence of cancer after HAART initiation in 8080 person-years of follow-up was 7.2 per 1000 person-years (95% confidence interval = 5.5 to 9.3) for ADC and 2.7 (95% confidence interval = 1.8 to 4.1) for NADC; incidence was higher in the first 2 months, particularly for ADC (47.6). A pre-HAART ADC was a predictor of mortality after adjusting for age, sex, and CD4 at HAART initiation.
CONCLUSIONS
ADC were the most frequent cancers in this region and were often diagnosed close to HIV diagnosis and HAART start. Incidence of cancer was highest around HAART initiation.
背景
HIV 感染者的癌症风险较高。随着高效抗逆转录病毒疗法(HAART)的出现,一些艾滋病定义性癌症(ADC)的频率已经降低,尽管某些非艾滋病定义性癌症(NADC)变得更加频繁。拉丁美洲和加勒比地区 HIV 感染者的癌症尚未得到仔细研究。
方法
通过审查临床记录和现有数据库,确定了加勒比、中美洲和南美洲 HIV 研究网络(CCASAnet)队列中的癌症病例。
结果
共报告了 406 例癌症:331 例 ADC(224 例卡波西肉瘤和 98 例非霍奇金淋巴瘤)。最常见的 NADC(n = 75)是霍奇金淋巴瘤和皮肤癌。73%的 NADC 和 45%的 ADC 在 HIV 诊断后 1 年以上被诊断。56%的 ADC 在 HAART 开始前被诊断。从 HAART 开始到癌症诊断的中位时间为 NADC 2.5 年,ADC 为 0.5 年(P <0.001)。在 3372 名开始 HAART 的患者中,有 158 人被诊断出患有 165 例癌症(82.4%为 ADC);85 例病例发生在 HAART 开始之前或同时。在 8080 人年的随访中,HAART 开始后癌症的发生率为每 1000 人年 7.2 例(95%置信区间为 5.5 至 9.3),ADC 为每 1000 人年 2.7 例(95%置信区间为 1.8 至 4.1);在前 2 个月,特别是 ADC 的发生率更高(47.6)。在调整了 HAART 开始时的年龄、性别和 CD4 后,HAART 前的 ADC 是死亡的预测因素。
结论
在该地区,ADC 是最常见的癌症,并且经常在 HIV 诊断和 HAART 开始时被诊断。癌症的发生率在 HAART 开始时最高。